慢阻肺疾病稳定患者的临床结局:韩国COPD亚组研究队列数据
本研究基于韩国COPD亚组研究前瞻性队列,纳入1639例≥40岁且支气管舒张后FEV1/FVC<0.70的COPD患者,比较第一年内达到疾病稳定(DS+)与未达到者(DS-)的临床结局。结果显示DS+患者中重度急性加重和重度急性加重发生率显著更低,全因死亡风险独立降低,但FEV1年下降幅度反而更大。
要点
- DS+定义为第一年内无中重度急性加重、FEV1无下降且SGRQ评分无恶化。
核心结论
- COPD患者达到疾病稳定(DS+)与急性加重减少和全因死亡风险降低独立相关,支持DS作为临床有意义的治疗目标。
研究设计与样本
- 韩国COPD亚组研究为全国性前瞻性队列,纳入≥40岁且支气管舒张后FEV1/FVC<0.70的COPD患者。
- 共分析1639例患者,其中147例(9.0%)为DS+,1492例(91.0%)为DS-。
- 十年全因死亡数据来自国家死亡记录并与队列数据合并。
关键数值与推荐
- DS+定义为第一年内无中重度急性加重、FEV1无下降且圣乔治呼吸问卷评分无恶化。
临床怎么用
- 可将疾病稳定作为COPD个体化管理的治疗目标之一,关注第一年内急性加重、肺功能和生活质量变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD is a heterogeneous disease with progressive airflow limitation. Despite therapeutic advances, current treatments poorly halt COPD progression. Disease stability (DS) is a proposed treatment goal, but its clinical significance remains uncertain. RESEARCH QUESTION: What are the differences in lung function decline, exacerbation risk, and mortality between patients with COPD with and without DS? STUDY DESIGN AND METHODS: This study analyzed data from the Korean COPD Subgroup Study, a nationwide prospective cohort of patients with COPD in South Korea. Participants were ≥ 40 years of age and had a postbronchodilator FEV1/FVC ratio < 0.70. Ten-year all-cause mortality data were obtained from national death records and merged with cohort data. DS (+) was defined as the absence of moderate-to-severe exacerbations, no decline in FEV1, and no worsening of the St. George's Respiratory questionnaire score during the first year. Clinical outcomes were compared between patients with DS (+) and patients without DS (+), who were classified as DS (-). RESULTS: Among 1,639 patients analyzed, 147 (9.0%) achieved DS (+), whereas 1,492 (91.0%) were classified as DS (-). Baseline characteristics were similar between groups. Compared with the DS (-) group, the DS (+) group exhibited significantly lower rates of moderate-to-severe exacerbations (incidence rate ratio, 0.30; P = .033) and severe exacerbations (incidence rate ratio, 0.26; P = .002). Paradoxically, the annual decline in FEV1 was greater in the DS (+) group (-45.8 vs -10.3 mL/y; P < .001). Multivariable Cox regression analysis demonstrated that DS (+) status was independently associated with a significantly reduced risk of all-cause mortality (adjusted hazard ratio, 0.56; P = .036). INTERPRETATION: Patients with COPD with DS (+) showed reduced exacerbations and mortality. These findings support DS as a clinically meaningful and achievable treatment target in COPD, with potential utility in guiding personalized disease management.
引用
- Son E, Seo H, Ra SW, et al. Clinical Outcomes in Patients With COPD With Disease Stability: Data from the Korea COPD Subgroup Study Cohort. Chest. 2025. PMID: 41207473. doi:10.1016/j.chest.2025.10.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。